Filing date | Form | Description | Filing Group | View |
---|---|---|---|---|
3/A | An amendment to a 3 filing. Non-EDGAR filing |
3,4,5
|
||
3/A | An amendment to a 3 filing. Non-EDGAR filing |
3,4,5
|
||
3/A | An amendment to a 3 filing. Non-EDGAR filing |
3,4,5
|
||
8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
||
8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
EX-101.INS - XBRL INSTANCE DOCUMENT | |
8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
4/A | Amendment to a previously filed 4 |
3,4,5
|
||
4/A | Amendment to a previously filed 4 |
3,4,5
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.